Selective enrichment of hypericin in malignant glioma: Pioneering in vivo results

  • Authors:
    • Susan Noell
    • Daniel Mayer
    • Wolfgang S.L. Strauss
    • Marcos S. Tatagiba
    • Rainer Ritz
  • View Affiliations

  • Published online on: March 10, 2011     https://doi.org/10.3892/ijo.2011.968
  • Pages: 1343-1348
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Malignant gliomas are diffuse infiltrative growing tumors with a poor prognosis despite treatment with a combination of surgery, radiotherapy and chemotherapy. It has been shown recently that complete tumor resection improves the survival time significantly. Hypericin, a component of St. Johns Wort, is one of the most powerful photosensitizers in nature. The aim of the present study was to investigate accumulation of hypericin in intracerebral implanted malignant glioma in vivo. Rats underwent stereotactic implantation of C6 glioma cells. After intravenous administration of hypericin (5 mg per kg body weight), accumulation of the compound was studied in tumor, the infiltration zone surrounding the tumor and healthy brain (contralateral hemisphere) by fluorescence microscopy between 0 and 48 h after injection. Results were compared by one-way analysis of variance. For post hoc pair-wise comparison the Tukey-Kramer HSD test was used. Accumulation of hypericin was significantly higher in C6 glioma as compared to normal tissue. Maximum hypericin uptake was achieved at 24 h after injection. Ratios of fluorescence intensity between tumor and normal tissue as well as infiltration zone and normal tissue of about 6.1:1 and 1.4:1 were found. Considering tissue auto-fluorescence, fluorescence ratios of about 19.8:1 and 2.5:1 were calculated, respectively. Therefore, hypericin seems to be quite an effective fluorescence marker for the detection of glioma in vivo. To the best of our knowledge, the present study demonstrates for the first time that hypericin accumulates selectively in intracerebral implanted C6 glioma in vivo after systemic (intravenous) administration.

Related Articles

Journal Cover

May 2011
Volume 38 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Noell S, Mayer D, Strauss WS, Tatagiba MS and Ritz R: Selective enrichment of hypericin in malignant glioma: Pioneering in vivo results. Int J Oncol 38: 1343-1348, 2011
APA
Noell, S., Mayer, D., Strauss, W.S., Tatagiba, M.S., & Ritz, R. (2011). Selective enrichment of hypericin in malignant glioma: Pioneering in vivo results. International Journal of Oncology, 38, 1343-1348. https://doi.org/10.3892/ijo.2011.968
MLA
Noell, S., Mayer, D., Strauss, W. S., Tatagiba, M. S., Ritz, R."Selective enrichment of hypericin in malignant glioma: Pioneering in vivo results". International Journal of Oncology 38.5 (2011): 1343-1348.
Chicago
Noell, S., Mayer, D., Strauss, W. S., Tatagiba, M. S., Ritz, R."Selective enrichment of hypericin in malignant glioma: Pioneering in vivo results". International Journal of Oncology 38, no. 5 (2011): 1343-1348. https://doi.org/10.3892/ijo.2011.968